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ALH = atypical lobular hyperplasia; DCIS = ductal carcinoma in situ; LCIS = lobular carcinoma in situ; LIN = lobular intraepithelial neoplasia; LN =
lobular neoplasia; PLCIS = pleomorphic LCIS.
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Introduction
Atypical lobular hyperplasia (ALH) and lobular carcinoma
in situ (LCIS) – lesions that are also referred to under the
umbrella heading of ‘lobular neoplasia’ (LN) – occur rela-
tively infrequently in the breast. However, problems and
controversies surrounding the most appropriate terminol-
ogy and classification for these lesions, and the best
course of long-term management after diagnosis, are far
from infrequent.
Foote and Stewart first coined the term LCIS in 1941 [1],
choosing the name to highlight the morphological similari-
ties between the cells of LCIS and those of frankly invasive
lobular carcinoma. They recognised parallels with ductal
carcinoma in situ (DCIS), namely foci of neoplastic cells
that were still contained within a basement membrane. In
anticipating that LCIS, like DCIS, was a step along the
pathway to invasive cancer, they recommended mastec-
tomy as the standard form of treatment; this management
plan was adopted for many years. The term ALH was sub-
sequently introduced to describe morphologically similar
but less well developed lesions. LN was a term introduced
by Haagensen in 1978 [2] to cover the full range of prolif-
eration, including both ALH and LCIS within the spectrum.
ALH and LCIS have since become well-established
histopathological entities in the classification of breast
neoplasia, but it has become clear over the past 60 years
that they are not precursor lesions for invasive carcinoma
in the same way as high-grade DCIS of comedo type
[3–6]. A diagnosis of ALH/LCIS today is often seen as a
‘risk indicator’ for subsequent carcinoma rather than a true
precursor. Radical surgical treatment has fallen out of
favour but there is a lack of consensus on what the most
appropriate management of patients diagnosed with
ALH/LCIS should be. Recommendations for treatment
vary from follow-up with regular mammography, to follow-
up alone or simply ‘no action’ [2,7,8]. However, recent
work is once again suggesting that LCIS is indeed a non-
obligate precursor lesion for carcinoma, a finding that
might have significant implications for the management of
patients diagnosed with this disease.
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Abstract
The term lobular neoplasia refers to a spectrum of lesions featuring atypical lobular hyperplasia and
lobular carcinoma in situ (LCIS). The histopathological characteristics of these lesions are well
documented. What is less well understood is the management implications of a patient diagnosed with
LCIS; treatment regimes vary and are somewhat controversial. LCIS is now considered a risk factor
and a non-obligate precursor for the subsequent development of invasive cancer.




LCIS is most frequently diagnosed in women aged
between 40 and 50 years (less than 10% of patients with
LCIS are postmenopausal), which is a decade earlier than
the age of women diagnosed with DCIS. Estimating the
incidence of LCIS is fraught with difficulty. There are no
specific clinical abnormalities, in particular no palpable
lump, and LCIS is only rarely visible on mammography
when an uncommon calcifying subtype is present [9,10].
When examining a pathological specimen, there are no
macroscopic features characteristic of LCIS. The diagno-
sis of LCIS is therefore usually an incidental finding in
breast biopsy performed for other indications. For these
reasons the true incidence of LCIS in the general popula-
tion is unknown, and many asymptomatic women presum-
ably go unnoticed. The incidence of LCIS in otherwise
benign breast biopsy is between 0.5% and 3.8% [2,11].
Characteristically, LCIS is multifocal and bilateral in a large
proportion of cases. Over 50% of patients diagnosed with
LN contain multiple foci in the ipsilateral breast and about
30% of cases will have further LCIS in the contralateral
breast [12–14]. This multifocality, in a clinically unde-
tectable lesion, is one of the reasons why planning subse-
quent management is so difficult.
Histological features of LN
The criteria for the histological diagnosis of ALH and LCIS
are well established. LCIS is composed of a monomorphic
population of usually small, round, polygonal or cuboidal
cells, with a thin rim of clear cytoplasm and a high nuclear-
cytoplasmic ratio (Fig.1). Cells containing clear vacuoles,
known as intracytoplasmic lumina or magenta bodies, are
often seen, and when they are identified in a fine needle
aspirate from the breast, they strongly suggest the pres-
ence of a lobular lesion (including ALH, LCIS and invasive
lobular carcinoma). The cells are loosely cohesive, regu-
larly spaced, and fill and distend the acini; however, overall
lobular architecture is maintained. Glandular lumina are
not seen, and mitoses, calcification and necrosis are
uncommon. Pagetoid spread, in which the neoplastic cells
extend along adjacent ducts, between intact overlying
epithelium and underlying basement membrane, is also
frequently seen.
The cells of classic LCIS, as described above, can also be
referred to as type A cells. Type B cells are a well-recog-
nised subtype of LCIS cells, with mildly to moderately
larger nuclei showing some increase in pleomorphism. A
more recently described entity is that of pleomorphic LCIS
(PLCIS). The cells in this lesion show more marked pleo-
morphism and distinctly larger nuclei with nucleoli. Central
necrosis and calcification within lobules are features of
note. In a situation analogous to ALH versus LCIS, there
might be some difficulty in terminology and practical differ-
entiation between a case of LCIS with type B cells and
that of PLCIS. Sneige and colleagues [15] have described
type B cells as containing nuclei that are up to double the
size of a lymphocyte (type A cells are 1–1.5 times larger),
whereas PLCIS nuclei are typically four times larger.
These subtypes might represent a spectrum of lesions,
but it is possible that PLCIS has different biological behav-
iour and implications from those of classic LCIS. It is
therefore important to recognise and document the pres-
ence of this variant.
For a diagnosis of LCIS, more than half the acini in an
involved lobular unit must be filled and distended by the
characteristic cells, leaving no central lumina (Fig.1). For
Figure 1
Differentiation of atypical lobular hyperplasia from lobular carcinoma in
situ is based on the extent of proliferation and the distension of the
lobular unit. In this case of atypical lobular hyperplasia (upper panel),
all acini are filled with neoplastic lobular type A cells (arrows), yet very
few are distorted. In contrast, the lower panel demonstrates that more
than 50% of acini are filled and distended, indicating a diagnosis of
lobular carcinoma in situ. Haematoxylin/eosin stain.260
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practical diagnostic purposes, distension translates as
eight or more cells present across the diameter of an
acinus. A lesion is regarded as ALH when it is less well
developed and less extensive than this, for instance when
the characteristic cells only partly fill the acini, with no or
only mild distension of the lobule (Fig.1). Lumina might
still be visible and the number of acini involved is less than
half. Myoepithelial cells can be seen admixed with the neo-
plastic population.
Clearly the differentiation between ALH and LCIS on
these criteria is somewhat arbitrary, and associated with
inter-observer and intra-observer variability. The use of the
term LN to encompass the whole range of changes might
therefore be preferable for diagnostic purposes. So far the
term has not gained widespread use among pathologists.
As discussed below, the justification for continuing to use
the ALH/LCIS terminology is that ALH has been shown to
have a lower risk than LCIS of subsequent invasive carci-
noma [11,16,17].
A further system for classification of these lesions has
been proposed by using the terminology ‘lobular intra-
epithelial neoplasia’ (LIN) and with subdivision, based on
morphological criteria and clinical outcome, into three
grades: LIN 1, LIN 2 and LIN 3 [18]. The assertion is that
the risk of subsequent invasive carcinoma is related to
increasing grade of LIN; however, there is as yet no con-
sensus of opinion, and data to support this view are pre-
liminary. In view of the rapid evolution in technology (see
the review on new technology in this series [19]), the clas-
sification systems are likely to undergo further change as
molecular data are incorporated. Hence, at present, it
does not seem prudent to introduce yet another interim
classification. We should take a lesson from the multiple
lymphoma classifications that led to considerable confu-
sion in patient management.
Differential diagnosis of LN
Occasional diagnostic difficulty can occur in cases in
which poor tissue preservation leads to an artefactual
appearance of discohesive cells within a lobular unit,
resulting in an overdiagnosis of LCIS. Another well-recog-
nised problem occurs when LCIS is superimposed on a
type of benign breast lesion known as sclerosing adeno-
sis, which causes a distortion of lobular units and a scle-
rotic stroma. The combination of abnormal architecture
and the proliferative lobular cells can easily be mistaken
for an invasive carcinoma by the unwary. In this situation,
immunohistochemistry to demonstrate the myoepithelial
cell layer or basement membrane can be useful in making
the distinction.
The most important, and the most difficult, differential diag-
nosis of LCIS is from low-nuclear-grade, solid DCIS. This
entity carries wholly different management implications for
the patient because it usually requires surgical excision,
whereas arguably, as discussed, LCIS might warrant no
further action. Correct identification is therefore essential.
However, distinction of LCIS from low-grade solid DCIS
can be very difficult because morphologically they can be
strikingly similar (Fig.2), especially when DCIS involves the
acini with minimal or no lobular distortion. The presence of
secondary lumen formation and cellular cohesion might
point to a ductal lesion rather than LCIS. Immunohisto-
chemical analysis of the lesion can prove useful because
E-cadherin, a cell membrane molecule involved in cell
adhesion, is typically absent in ALH/LCIS but present in
DCIS (see the review on molecular genetics in this series
[20]). In addition the expression of high-molecular-mass
cytokeratin (CK34βE12) is usually seen in LCIS but not in
DCIS [21]. Occasionally, lesions show a combination of
markers, suggesting that LCIS and low-grade solid DCIS
can coexist within the same duct-lobular unit. In these cir-
cumstances, differentiation between the two is often not
possible and both diagnoses should be given.
Implications of LN
Although it is clear that LCIS is not an obligate precursor
to invasive lobular carcinoma, many studies have shown
that a proportion of women with LCIS go on to develop
invasive carcinoma, with a risk of 6.9 times to about 12
times that of women without LCIS [2,22].
Page and colleagues [11,16] reported that the relative risk
of subsequently developing breast cancer was different in
patients diagnosed with ALH compared with LCIS.
Patients diagnosed with ALH have a risk of 4–5 times that
of the general population (namely women, of comparable
age, who have had a breast biopsy performed with no
diagnosis of proliferative disease) [16,17]. This relative
risk is doubled to 8–10 times for LCIS [11]. Thus,
although LN is a helpful term for describing these lesions
collectively, classification into ALH and LCIS might still be
justified, or preferable for risk stratification and manage-
ment decisions.
Data accumulated from nine separate studies revealed
that 15% of 172 patients diagnosed with LCIS developed
invasive carcinoma in the ipsilateral breast, and 9.3% of
204 patients developed invasive carcinoma in the con-
tralateral breast [23]. The development of contralateral
breast cancer is three times more likely in patients diag-
nosed with LCIS than without LCIS [24]. The risk of devel-
oping breast cancer is therefore also bilateral [12].
Reports have suggested that this risk is equal to both
breasts; however, corroborating studies demonstrate that
carcinoma is three times more likely to develop in the ipsi-
lateral relative to the contralateral breast [16,25,26].
The time taken to develop invasive cancer after diagnosis
of LCIS is unclear. Page and colleagues [11] reported that261
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two-thirds of women who developed invasive cancer did
so within 15 years of biopsy, yet in a separate study over
50% of cases who developed cancer did so between 15
and 30 years after biopsy, with an average interval of 20.4
years [27].
Both invasive ductal carcinoma and invasive lobular carci-
noma occur with LCIS. The coexistence of DCIS and
LCIS might explain the invasive ductal carcinoma compo-
nent observed, by which DCIS and not LCIS is the likely
precursor lesion [28,29]. Evidence for the role of LCIS as
a precursor for invasive lobular carcinoma is supported by
the epidemiological data outlined above, the morphologi-
cal similarity between cells of ALH/LCIS and lobular carci-
noma and the development of tumours in regions localised
to ALH/LCIS. Work on molecular aspects of lobular
lesions, in particular that focusing on the marker E-cad-
herin, add to this view (see the review on molecular genet-
ics in this series [20]).
Thus, the evidence, that 10–20% of patients identified
with LCIS develop breast carcinoma in the 15–25 years
after initial diagnosis, is compelling. Identifying this sub-
group of individuals is not easy by current clinical or mor-
phological means, although both morphological
classifications and the use of E-cadherin have been sug-
gested. Clearly further characterisation of these small
lesions is necessary to disentangle the current problems
faced in classification and management. It is hoped that
This article is the third in a review series on 
The diagnosis and management of pre-invasive breast
disease — current challenges, future hopes, edited by
Sunil R Lakhani.




Differential diagnosis is often difficult between lobular carcinoma in situ (arrow in upper left panel) and low-nuclear-grade, solid ductal carcinoma in
situ (upper right panel). Both lesions exhibit characteristic small monomorphic cells with a high nuclear-cytoplasmic ratio (high-power views, lower
middle and lower right panels, respectively). In contrast, high-grade ductal carcinoma in situ (arrowhead in upper left panel; high-power view, lower
left panel) exhibits markedly different histopathological features, notably the cohesiveness of neoplastic cells, pleomorphic nuclei and abundant
eosinophilic-to-amphiphilic cytoplasm. Haematoxylin/eosin stain.262
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the application of microdissection techniques and recently
developed molecular technology will hold the key to our
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